<DOC>
	<DOCNO>NCT00054561</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy isotretinoin use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth tumor cell . Vitamin E may able decrease side effect cause isotretinoin . It yet know whether combine isotretinoin interferon alfa vitamin E effective observation prevent recurrence head neck cancer surgery and/or radiation therapy . PURPOSE : Randomized phase III trial compare effectiveness isotretinoin interferon alfa combine vitamin E observation treat patient undergone surgery and/or radiation therapy stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Isotretinoin , Interferon Alfa , Vitamin E Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy adjuvant isotretinoin , interferon alfa , vitamin E , term incidence primary disease recurrence secondary primary tumor development , patient stage III IV squamous cell carcinoma head neck previously treat definitive surgical excision and/or postoperative radiotherapy . - Determine qualitative quantitative toxicity regimen patient . - Compare overall disease-free survival patient treat regimen v undergo observation . - Determine whether alteration p53 gene , retinoic acid receptor , retinoid-regulated gene , interferon-responsive gene associate clinical outcome patient . OUTLINE : This randomize , multicenter study . Patients stratify accord T stage ( T1 T2 v T3 T4 ) , N stage ( N0 N1 v N2 N3 ) , prior therapy ( complete tumor resection v resection radiotherapy/chemoradiotherapy v radiotherapy chemoradiotherapy alone ) , prior chemotherapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral isotretinoin daily , interferon alfa subcutaneously 3 time weekly , oral vitamin E 3 time daily . Treatment repeat every month 12 course ( 1 year ) absence disease recurrence unacceptable toxicity . - Arm II : Patients undergo observation 1 year . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 376 patient ( 188 per treatment arm ) accrue study within 3.75 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Primary site must within oral cavity , oropharynx , larynx , hypopharynx Stage III IV primary lesion diagnosis No distant metastatic disease diagnosis No multiple primary lesion Currently diseasefree treatment 1 following : Complete tumor resection Radiotherapy chemoradiotherapy alone* Resection follow radiotherapy/chemoradiotherapy* No 416 week since prior surgery and/or radiotherapy/chemoradiotherapy NOTE : *Radiotherapy must 7072 Gy 1.82.0 Gy fraction primary tumor clinically positive neck node 4450 Gy 1.82.0 Gy fraction clinically negative node , include low neck PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal Creatinine great 1.2 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month prior , , 1 month study therapy Electrolytes normal Fasting serum triglyceride level great 2 time ULN ( antitriglyceride medication allow ) No malignancy within past 2 year except localize basal cell squamous cell skin cancer No concurrent medical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy recover Prior neoadjuvant chemotherapy allow Prior chemotherapy administer concurrently radiotherapy allow No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics Recovered prior radiotherapy Surgery See Disease Characteristics Recovered prior surgery Other No history megadose vitamin A ( 25,000 I.U . ) No clinical trial enrollment would preclude adjuvant systemic therapy No concurrent vitamin supplement contain vitamin A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
</DOC>